Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1675 of 3499 entries
View as:

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

Phase: N/A Priority: Normal
NCT ID: NCT00001685 Org: User:
Start: 11/30/97 End: 09/30/00 Due: 09/30/01

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00075634 Org: User:
Start: 12/31/03 End: - Due: -

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00720109 Org: User:
Start: 07/14/08 End: 03/31/20 Due: 03/31/21

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00612612 Org: User:
Start: 01/31/08 End: - Due: -

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02007200 Org: User:
Start: 07/31/09 End: 09/30/15 Due: 09/30/16

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04847050 Org: User:
Start: 04/28/21 End: 05/25/23 Due: 05/25/24

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00499369 Org: User:
Start: 06/30/07 End: 11/30/12 Due: 11/30/13

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00182689 Org: User:
Start: 07/31/05 End: 10/31/08 Due: 10/31/09

Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study

Phase: N/A Priority: Normal
NCT ID: NCT01365975 Org: User:
Start: 06/01/11 End: 03/02/20 Due: 03/02/21

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00026182 Org: User:
Start: 10/31/01 End: - Due: -

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01061749 Org: User:
Start: 11/30/09 End: 09/30/14 Due: 09/30/15

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00039611 Org: User:
Start: 05/31/02 End: 10/31/07 Due: 10/31/08

Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study

Phase: N/A Priority: Normal
NCT ID: NCT00342394 Org: User:
Start: 11/14/01 End: 05/01/13 Due: 05/01/14

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00262834 Org: User:
Start: 10/31/05 End: 05/31/13 Due: 05/31/14

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00032045 Org: User:
Start: 01/31/02 End: 08/31/06 Due: 08/31/07

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01849263 Org: User:
Start: 04/02/13 End: 03/19/26 Due: 03/19/27

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00217646 Org: User:
Start: 10/31/05 End: - Due: -

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00095563 Org: User:
Start: 09/30/04 End: 06/30/09 Due: 06/30/10

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Phase: N/A Priority: Normal
NCT ID: NCT00748657 Org: User:
Start: 09/22/08 End: 01/31/13 Due: 01/31/14

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00109811 Org: User:
Start: 03/31/05 End: - Due: -

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00104871 Org: User:
Start: 12/31/04 End: 04/30/14 Due: 04/30/15

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Phase: N/A Priority: Normal
NCT ID: NCT04439253 Org: User:
Start: 08/12/15 End: 03/17/26 Due: 03/17/27

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00112476 Org: User:
Start: 03/31/05 End: - Due: -

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Phase: N/A Priority: Normal
NCT ID: NCT00003368 Org: User:
Start: 06/30/98 End: 07/31/06 Due: 07/31/07

Vorinostat in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00305773 Org: User:
Start: 01/31/06 End: 01/31/10 Due: 01/31/11